Overview

Progevera 10 mg® Versus Orgalutran® in Ovarian Stimulation Cycles of Oocyte Donors

Status:
Completed
Trial end date:
2017-07-10
Target enrollment:
Participant gender:
Summary
Evaluation of efficacy and safety of medroxiprogesterone acetate (Progevera 10 mg®) versus GnRh antagonist (Orgalutran®) in ovarian stimulation cycles of oocyte donors
Phase:
Phase 4
Details
Lead Sponsor:
Fundació Privada Eugin
Treatments:
Ganirelix